AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Equillium, Inc.
Video analysis: EQ
All videosNo video analysis for this stock yet. Request one from our team.
News: EQ
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C.
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update highlighting continued progress in support of EQ504, its potent and selective aryl hydrocarbon receptor (AhR) modulator.
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake
Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data-driven software and solutions that empowers brands to better understand, acquire, and retain their most valuable customers, today announced a three-year renewal and expansion of its partnership with a leading Canadian publisher, including the adoption of a SaaS license for its proprietary ClearLake platform. Under the expanded agreement, the publisher's internal teams will gain direct access to ClearLake to independently conduct advanced customer, competitor, and market research using EQ Works' proprietary data and analytics.
Similar companies
-
Cue Biopharma, Inc.
CUE
·
NASDAQ
Compare
-
NRx Pharmaceuticals, Inc.
NRXP
·
NASDAQ
Compare
-
OS Therapies Incorporated
OSTX
·
New York Stock Exchange Arca
Compare
-
Century Therapeutics, Inc.
IPSC
·
NASDAQ
Compare
-
Telomir Pharmaceuticals, Inc. Common Stock
TELO
·
NASDAQ
Compare
-
Outlook Therapeutics, Inc.
OTLK
·
NASDAQ
Compare